Oslo University Hospital Launches Phase 2 ALS Trial of ILB®
Oslo University Hospital has officially announced the commencement of a multicenter randomized phase 2 trial aimed at evaluating the efficacy of ILB® in patients diagnosed with amyotrophic lateral sclerosis (ALS). This exciting study is set to begin in early 2026 and aims to provide critical insights into potential new treatments for ALS, a devastating neurodegenerative disease.
Study Overview and Design
The study will enroll 116 patients, who will participate over a period of 12 months. This trial is specifically designed to compare ILB®, a novel treatment, against Riluzole, which is currently the standard of care for ALS patients. To ensure rigorous scientific evaluation, the trial will be conducted in two distinct phases: a six-month double-blind period followed by a six-month open-label extension.
Double-Blind Randomized Phase
During the first six months, participants will be randomly assigned to receive either ILB® or Riluzole under a double-blind protocol, where neither the investigator nor the participants will know which treatment is being administered. This approach is essential for minimizing biases, ensuring that the results will be as accurate and reliable as possible.
Open-Label Extension Phase
Following the double-blind phase, the study will transition into an open-label extension where all participants will receive ILB® alongside Riluzole. This phase is designed to gather further data on the long-term effects of ILB® and how well it works in combination with existing treatments.
Regulatory Approvals and Funding
The study has received all necessary regulatory approvals and is poised to start patient enrollment in the first quarter of 2026. Funding for the trial is primarily sourced from public research grants, emphasizing its focus on advancing medical science for ALS rather than commercial intent.
Role of Tikomed in the Trial
Tikomed, the pharmaceutical company behind ILB®, will supply the medication for both phases of the study. In addition, they will provide a placebo for the randomized controlled trial (RCT) portion, ensuring that the research is conducted under the highest scientific standards.
Understanding ALS
Amyotrophic lateral sclerosis, commonly referred to as ALS, is a progressive neurodegenerative disease that affects nerves in the brain and the spinal cord. Approximately 250,000 to 300,000 individuals worldwide live with this condition. Sadly, it often leads to severe physical disabilities and has a prognosis that usually sees life expectancy decreasing significantly after diagnosis.
Patient Impact and Core Symptoms
Patients diagnosed with ALS experience a dramatic decline in motor function, which can manifest through difficulty swallowing and breathing. These symptoms severely impact quality of life, making advancements in treatment options critical for the ALS community.
About Tikomed
Tikomed is a pioneering pharmaceutical company based in Viken, Sweden. The company is dedicated to developing innovative therapies for neurodegenerative diseases, and ILB® is at the forefront of their initiatives. Clinical trials have shown that ILB® possesses a favorable safety profile, with initial studies indicating it may hold promise for ALS treatment.
Contact Information
For further inquiries regarding the trial or ILB®, Tikomed's Chief Medical Officer Dr. Björn Pilström is available for contact through their official channels. Their commitment to improving care and outcomes for those suffering from neurodegenerative conditions is evident in their ongoing research efforts.
Frequently Asked Questions
What is the objective of the phase 2 trial for ILB®?
The objective of the trial is to evaluate the efficacy of ILB® compared to the current standard of care, Riluzole, in ALS patients.
How many patients will participate in the trial?
The trial will include 116 patients who will be monitored over a 12-month period.
When is the trial expected to start enrolling patients?
Patient enrollment is set to begin in the first quarter of 2026.
What role does Tikomed play in this trial?
Tikomed will supply ILB® and placebo for the trial phases, ensuring the study's integrity and scientific rigor.
Why is further research important for ALS?
Further research is crucial as ALS is a debilitating condition with no curative treatments available, highlighting the need for more effective therapies.
